Oryzon Genomics S.A. (LON:0RDB)

Market Cap	173.14M
Revenue (ttm)	6.09M
Net Income (ttm)	-3.03M
Shares Out	n/a
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	211
Average Volume	9,476
Open	2.760
Previous Close	n/a
Day's Range	2.735 - 2.760
52-Week Range	1.602 - 2.760
Beta	n/a
RSI	43.62
Earnings Date	May 9, 2025

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical developme...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2000
• Employees: 47
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RDB

Financial Performance

In 2024, Oryzon Genomics's revenue was 7.36 million, a decrease of -48.15% compared to the previous year's 14.19 million. Losses were -3.67 million, 9.32% more than in 2023.

Financial numbers in EUR